ICON plc shares traded higher Thursday, April 2, 2026, with the move largely tied to a rebound in sentiment following a prominent Wall Street upgrade last week. BMO upgraded ICON to Outperform on March 26, 2026 and lifted its price target to $130, a constructive signal for investors after months of uncertainty tied to delayed financial reporting and an ongoing investigation into accounting practices. (benzinga.com)

The key unresolved issue remains ICON’s delayed fourth-quarter and full-year 2025 results. ICON said on Feb. 12, 2026 it intends to release those results on or prior to April 30, 2026, while the audit committee’s investigation—primarily focused on revenue recognition across fiscal years 2023 through 2025—continues. The company also warned it expects to report one or more material weaknesses in internal control over financial reporting, and preliminary indications suggested 2023 and 2024 revenue may have been overstated by less than 2% in each year. (investor.iconplc.com)

Beyond the upgrade, positioning has been incrementally improving. Reported short interest fell about 3.6% to roughly 1.93 million shares as of Feb. 27, 2026 versus the prior reporting period, reducing some near-term pressure and leaving room for rebounds on positive catalysts. (marketbeat.com)

The next catalyst is the company’s delayed earnings release deadline (on or before April 30, 2026). Investors are likely to trade the stock on (1) whether ICON meets that timetable, (2) the magnitude and scope of any revisions tied to revenue recognition, and (3) whether management commentary suggests stabilizing demand in outsourced clinical development and durable client relationships despite the investigation.